| Integrating circulating-free DNA (cfDNA) analysis into clinical practice: Opportunities and challenges M Garcia-Pardo, M Makarem, JJN Li, D Kelly, NB Leighl British Journal of Cancer 127 (4), 592-602, 2022 | 58 | 2022 |
| Association of circulating tumor DNA testing before tissue diagnosis with time to treatment among patients with suspected advanced lung cancer: the accelerate nonrandomized … M García-Pardo, K Czarnecka-Kujawa, JH Law, AM Salvarrey, ... JAMA Network Open 6 (7), e2325332-e2325332, 2023 | 14 | 2023 |
| Plasma-first: accelerating lung cancer diagnosis and molecular profiling through liquid biopsy M Garcia-Pardo, K Czarnecka, JH Law, A Salvarrey, R Fernandes, J Fan, ... Therapeutic Advances in Medical Oncology 14, 17588359221126151, 2022 | 14 | 2022 |
| Vaccine Therapy in Non-Small Cell Lung Cancer M García-Pardo, T Gorria, I Malenica, S Corgnac, C Teixidó, L Mezquita Vaccines 10 (5), 740, 2022 | 13 | 2022 |
| ROS-1 NSCLC therapy resistance mechanism M García-Pardo, A Calles Precision Cancer Medicine 4, 2021 | 13 | 2021 |
| Molecular Profiling and Targeted Therapy in Cholangiocarcinoma: An Observational, Retrospective Multicenter Study M Garcia-Pardo, L Ortega, MJ Fernández-Aceñero, P García Alfonso, ... Journal of Gastrointestinal Cancer 52, 814-818, 2021 | 6 | 2021 |
| Respiratory and Cardiometabolic Comorbidities and Stages I to III NSCLC Survival: A Pooled Analysis From the International Lung Cancer Consortium M García-Pardo, A Chang, S Schmid, M Dong, MC Brown, D Christiani, ... Journal of Thoracic Oncology 18 (3), 313-323, 2023 | 5 | 2023 |
| Plasma-based genotyping in advanced solid tumors: a comprehensive review M Makarem, M García-Pardo, NB Leighl Cancers 13 (21), 5299, 2021 | 4 | 2021 |
| Brief Report: Clinical Outcomes Using Plasma-Based Molecular Profiling to Guide Treatment Decisions in Patients With Advanced NSCLC and Limited Access to Broad Tissue Testing M García-Pardo, I Aparicio, Í Martínez, M Arregui, V Tirado, M Galera, ... Clinical Lung Cancer 24 (4), 366-370, 2023 | 3 | 2023 |
| Geographic differences in lung cancer: focus on carcinogens, genetic predisposition, and molecular epidemiology JC Laguna, M García-Pardo, J Alessi, C Barrios, N Singh, HO Al-Shamsi, ... Therapeutic Advances in Medical Oncology 16, 17588359241231260, 2024 | 2 | 2024 |
| A phase-1 dose escalation and expansion study of EP0031, a next-generation selective RET inhibitor (SRI), in patients with SRI-naïve or pretreated advanced RET-altered NSCLC … E Garralda, JS Wang, AG Gianoukakis, MH Taylor, DR Spigel, ... Journal of Clinical Oncology 42 (16_suppl), 8556-8556, 2024 | | 2024 |
| Single organ metastatic sites in non-small cell lung cancer: Patient characteristics, treatment patterns and outcomes from a large retrospective Canadian cohort Y Li, M Wong, L Zhan, L Corke, MC Brown, S Cheng, K Khan, ... Lung Cancer 192, 107823, 2024 | | 2024 |
| The sooner, the better: early clearance of plasma circulating tumor DNA in patients with advanced KRAS G12C mutant non-small cell lung cancer M García-Pardo, P Garrido Translational Lung Cancer Research 13 (2), 215, 2024 | | 2024 |
| A New Frontier in the Treatment of Epidermal Growth Factor Receptor-mutated Non–Small-Cell Lung Cancer: Amivantamab-vmjw and Chemotherapy. M García-Pardo, P Garrido touchREVIEWS in Oncology & Haematology 20 (1), 2024 | | 2024 |
| IPSOS trial: A “game changer” redefining first-line immunotherapy in platinum-ineligible NSCLC M García-Pardo, L Mezquita Med 4 (11), 745-748, 2023 | | 2023 |
| Negative Predictive Value of Pre-diagnostic Plasma ctDNA Testing in Patients With Suspected Lung Cancer M García-Pardo, K Czarnecka-Kujawa, L Le, T Waddell, K Yasufuku, ... The Journal of Liquid Biopsy 1, 2023 | | 2023 |
| P1. 22-04 Plasma-First to Accelerate Time to Treatment and Improve Target Detection in Advanced Lung Cancer: A Prospective Study MG Pardo, K Czarnecka, JH Law, ZJ Fan, TK Waddell, K Yasufuku, G Liu, ... Journal of Thoracic Oncology 18 (11), S245-S246, 2023 | | 2023 |
| “Plasma-first” approach for molecular genotyping in non-small cell lung cancer: A narrative review M García-Pardo, N Leighl The Journal of Liquid Biopsy, 100123, 2023 | | 2023 |
| Re: Response to Letter to the Editor “Respiratory and Cardiometabolic Comorbidities and Stage I-III Non-Small Cell Lung Cancer (NSCLC) Survival: A Pooled Analysis From the … M García-Pardo, G Liu Journal of Thoracic Oncology 18 (9), e96-e97, 2023 | | 2023 |
| Real world challenges in defining oligometastatic disease in clinical practice. I Navarro-Domenech, AS Barry, J Tsai, G Ma, M García-Pardo, I Hirsch, ... Journal of Clinical Oncology 41 (16_suppl), e18873-e18873, 2023 | | 2023 |
